ASCO 2025: Dual-target CAR T-cell therapy slows growth of aggressive brain cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumour growth in glioblastoma. Tumours became…
A dual-target CAR T cell therapy approach shows promise for slowing tumour growth in glioblastoma. Tumours became…
The results of an international phase 3 clinical trial sponsored by the National Cancer Institute,…
Results from the Phase 3, randomised, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia…
A large prospective, randomised clinical trial in patients with advanced breast cancer has found that…
New study results show that a structured exercise programme following surgery and adjuvant chemotherapy reduced…
Results from an international phase 3 clinical trial found that treating stage II, III, and…
A phase 2 trial reports high response rates and durable outcomes in treatment-naive patients, presented…
New data, to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting…
A new study presented today by researchers at Fox Chase Cancer Center shows that some…
Thomas E. Hutsonchief of the Haematology Oncology Division at Texas Tech University Health Sciences Centre,…